Description

Simple

A medication used to treat multiple sclerosis, a disease causing the immune system to attack nerves.

Clinical

A monoclonal anti-CD25 antibody that blocks the interleukin-2 receptor which is used to treat relapsing forms of multiple sclerosis.

Overview

Humanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). Daclizumab is a composite of human (90%) and murine (10%) antibody sequences. The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody. The murine sequences were derived from the complementarity-determining regions of a murine anti-Tac antibody.

On 22 April 2008, Roche Registration Limited chose to voluntarily withdraw the marketing authorization for their product Zenapax (daclizumab), as indicated for the prophylaxis of acute organ rejection in de novo allogeneic renal transplantation and used concomitantly with an immunosuppressive regimen like cyclosporine and corticosteroids in patients who are not hight immunized, for commercial reasons and confirmed that this decision was not related to any safety concerns associated with the use of Zenapax (daclizumab) [2]. Regardless of the withdrawal of Zenapax, Biogen and Abbvie's Zinbryta (daclizumab), as indicated for the treatment of adult patients with relapsing forms of multiple sclerosis, was approved for use by the FDA in 2016 [3].

Despite being approv... Read more

Pharmacology

Indication

Zenapax is a humanized monoclonal antibody used for prevention of renal transplant rejection

Pharmacodynamic

Zenapax functions as an IL-2 receptor antagonist. Specifically it inhibits IL-2-mediated activation of lymphocytes, a critical pathway in the cellular immune response involved in allograft rejection.

Mechanism of action

Zenepax binds with high-affinity to the Tac subunit of the high-affinity IL-2 receptor complex and inhibits IL-2 binding. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes.

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

11-38 days

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

  • Regions: US
  • Patient Conditions:
      • Name: History of autoimmune hepatitis
      • Drugbank Id: DBCOND0107475
  • Regions: US
  • Patient Conditions:
      • Name: Hepatic Impairment
      • Drugbank Id: DBCOND0031585
  • Regions: US
  • Patient Conditions:
      • Name: Pre-existing hepatic disease
      • Drugbank Id: DBCOND0107474
  • Regions: US
  • Patient Conditions:
      • Name: Autoimmune condition involving the liver
      • Drugbank Id: DBCOND0107476

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Daclizumab
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
2-Methoxyethanol
The risk or severity of adverse effects can be increased when Daclizumab is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
The risk or severity of adverse effects can be increased when Daclizumab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
The risk or severity of adverse effects can be increased when Daclizumab is combined with Abatacept.
Abciximab
The risk or severity of adverse effects can be increased when Abciximab is combined with Daclizumab.
Abetimus
The risk or severity of adverse effects can be increased when Daclizumab is combined with Abetimus.
Abituzumab
The risk or severity of adverse effects can be increased when Daclizumab is combined with Abituzumab.
Abrilumab
The risk or severity of adverse effects can be increased when Daclizumab is combined with Abrilumab.
Acteoside
The risk or severity of adverse effects can be increased when Daclizumab is combined with Acteoside.
Adalimumab
The risk or severity of adverse effects can be increased when Adalimumab is combined with Daclizumab.
Adecatumumab
The risk or severity of adverse effects can be increased when Daclizumab is combined with Adecatumumab.
Adenovirus type 7 vaccine live
The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Daclizumab.
Aducanumab
The risk or severity of adverse effects can be increased when Daclizumab is combined with Aducanumab.
Afelimomab
The risk or severity of adverse effects can be increased when Daclizumab is combined with Afelimomab.
Aldesleukin
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Daclizumab.
Aldosterone
The risk or severity of adverse effects can be increased when Daclizumab is combined with Aldosterone.
Alefacept
The risk or severity of adverse effects can be increased when Alefacept is combined with Daclizumab.
Alemtuzumab
The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Daclizumab.
Alirocumab
The risk or severity of adverse effects can be increased when Daclizumab is combined with Alirocumab.
Altretamine
The risk or severity of adverse effects can be increased when Daclizumab is combined with Altretamine.
Amatuximab
The risk or severity of adverse effects can be increased when Daclizumab is combined with Amatuximab.
3 References
  1. 1 . U.S. Food & Drug Administration: FDA working with manufacturers to withdraw Zinbryta from the market in the United States Link
  2. 2 . European Medicines Agency: Public state on Zenapax (daclizumab), Withdrawal of the marketing authorization in the European Union Link
  3. 3 . U.S. FDA Zinbryta (daclizumab) Prescribing Information Link